These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25041231)

  • 21. FDA Approval of Extended-Release Oxycodone for Children With Severe Pain.
    Yang YT; Chen B; Bennett CL
    Pediatrics; 2016 May; 137(5):. PubMed ID: 27244829
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program.
    Keast SL; Owora A; Nesser N; Farmer K
    J Manag Care Spec Pharm; 2016 Apr; 22(4):347-56. PubMed ID: 27023688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
    Webster LR; Markman J; Cone EJ; Niebler G
    Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Morphine or oxycodone tablets for pain?].
    Fredheim OM; Dale O; Kaasa S; Borchgrevink PC
    Tidsskr Nor Laegeforen; 2010 Aug; 130(15):1479-81. PubMed ID: 20706310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new abuse-deterrent opioid--Xtampza ER.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):77-8. PubMed ID: 27305067
    [No Abstract]   [Full Text] [Related]  

  • 26. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Don't tamper with oxycodone.
    Fletcher J; Tsuyuki R
    CMAJ; 2013 Feb; 185(2):107. PubMed ID: 23296585
    [No Abstract]   [Full Text] [Related]  

  • 28. Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain.
    Anastassopoulos KP; Chow W; Tapia CI; Baik R; Ackerman SJ; Biondi D; Kim MS
    J Manag Care Pharm; 2012 Oct; 18(8):615-26. PubMed ID: 23127149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.
    Cicero TJ; Ellis MS; Kasper ZA
    Pain; 2016 Jun; 157(6):1232-1238. PubMed ID: 27186712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?
    Raffa RB; Taylor R; Pergolizzi JV
    Expert Opin Drug Saf; 2014 Feb; 13(2):181-90. PubMed ID: 24206269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges in the development of prescription opioid abuse-deterrent formulations.
    Katz NP; Adams EH; Chilcoat H; Colucci RD; Comer SD; Goliber P; Grudzinskas C; Jasinski D; Lande SD; Passik SD; Schnoll SH; Sellers E; Travers D; Weiss R
    Clin J Pain; 2007 Oct; 23(8):648-60. PubMed ID: 17885342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain.
    Brushwood DB; Rich BA; Coleman JJ; Bolen J; Wong W
    J Pain Palliat Care Pharmacother; 2010 Dec; 24(4):333-48. PubMed ID: 21133741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.
    Cicero TJ; Surratt H; Inciardi JA; Munoz A
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):827-40. PubMed ID: 17636553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Companies to pay $39.5m in OxyContin and Risperdal cases.
    McCarthy M
    BMJ; 2015 Dec; 351():h7018. PubMed ID: 26721284
    [No Abstract]   [Full Text] [Related]  

  • 35. Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl.
    Kirson NY; White AG; Birnbaum HG; Schiller M; Waldman T; Peterson K; Ben-Joseph RH; Berner T; Summers KH
    J Med Econ; 2012; 15(1):87-95. PubMed ID: 22032675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA actions to prevent prescription drug abuse.
    Jeske AH
    Tex Dent J; 2005 Jul; 122(7):634-45. PubMed ID: 16152888
    [No Abstract]   [Full Text] [Related]  

  • 37. Modeling the potential impact of abuse-deterrent opioids on medical resource utilization.
    Yenikomshian MA; White AG; Carson ME; Jia ZB; Mendoza MR; Roland CL
    J Med Econ; 2019 Oct; 22(10):1073-1079. PubMed ID: 31314616
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
    Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
    J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic costs of nonmedical use of prescription opioids.
    Hansen RN; Oster G; Edelsberg J; Woody GE; Sullivan SD
    Clin J Pain; 2011; 27(3):194-202. PubMed ID: 21178601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
    Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC
    Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.